CN118453493A - D2o稳定化的药物制剂 - Google Patents

D2o稳定化的药物制剂 Download PDF

Info

Publication number
CN118453493A
CN118453493A CN202410210163.6A CN202410210163A CN118453493A CN 118453493 A CN118453493 A CN 118453493A CN 202410210163 A CN202410210163 A CN 202410210163A CN 118453493 A CN118453493 A CN 118453493A
Authority
CN
China
Prior art keywords
ophthalmic
composition
less
months
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410210163.6A
Other languages
English (en)
Chinese (zh)
Inventor
格雷戈里·I·奥斯特罗夫
肯尼斯·J·威德
大卫·S·贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sydnexis Inc
Original Assignee
Sydnexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sydnexis Inc filed Critical Sydnexis Inc
Publication of CN118453493A publication Critical patent/CN118453493A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410210163.6A 2015-05-29 2016-05-27 D2o稳定化的药物制剂 Pending CN118453493A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562168538P 2015-05-29 2015-05-29
US62/168,538 2015-05-29
CN201680043657.3A CN107847432A (zh) 2015-05-29 2016-05-27 D2o稳定化的药物制剂
PCT/US2016/034823 WO2016196367A1 (en) 2015-05-29 2016-05-27 D2o stabilized pharmaceutical formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680043657.3A Division CN107847432A (zh) 2015-05-29 2016-05-27 D2o稳定化的药物制剂

Publications (1)

Publication Number Publication Date
CN118453493A true CN118453493A (zh) 2024-08-09

Family

ID=57442106

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410210163.6A Pending CN118453493A (zh) 2015-05-29 2016-05-27 D2o稳定化的药物制剂
CN201680043657.3A Pending CN107847432A (zh) 2015-05-29 2016-05-27 D2o稳定化的药物制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680043657.3A Pending CN107847432A (zh) 2015-05-29 2016-05-27 D2o稳定化的药物制剂

Country Status (6)

Country Link
US (5) US11052094B2 (https=)
EP (1) EP3302426A4 (https=)
JP (1) JP2018521000A (https=)
CN (2) CN118453493A (https=)
HK (1) HK1248570A1 (https=)
WO (1) WO2016196367A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
CA3037176A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
JP7138103B2 (ja) 2016-11-29 2022-09-15 オキュリス エスエー 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
WO2018193367A1 (en) * 2017-04-19 2018-10-25 Zenvision Pharma Llp Novel pharmaceutical composition comprising combination of alcaftadine and nepafenac along with antibacterial and/or antiviral an/or antifungal drug
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
CN109706238B (zh) 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法
US10293047B1 (en) 2017-11-15 2019-05-21 Paragon BioTeck, Inc. Fluorescein and benoxinate compositions
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
US20190209471A1 (en) * 2018-01-11 2019-07-11 Panaseea, LLC Buffered compositions and methods for their use in surface treatments
EP3761953A1 (en) 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
HUE058931T2 (hu) 2018-04-24 2022-09-28 Allergan Inc Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
KR20240014102A (ko) * 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
AU2019299942A1 (en) * 2018-07-11 2021-01-28 Parenteral Technologies, Llc Highly concentrated formulations and methods for producing large batch pharmaceutical formulations
CN109010268B (zh) * 2018-09-28 2020-07-10 湖北远大天天明制药有限公司 一种提高氯霉素稳定性的眼用组合物及其制备方法
US20210369648A1 (en) * 2018-10-06 2021-12-02 Biotheravision Llc Cysteamine zinc complex and method of using a cysteamine zinc complex
IL283127B1 (en) 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
CN109674758A (zh) * 2019-02-25 2019-04-26 湖南博隽生物医药有限公司 一种用于治疗癫痫的双丙戊酸钠缓释片及其制备方法
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
US11071724B2 (en) * 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
EP4670738A3 (en) 2019-07-01 2026-03-04 Oculis Operations Sàrl Method for stabilizing the ph of an aqueous composition comprising a drug
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN115996742A (zh) * 2020-03-25 2023-04-21 奥夫博医疗创新有限公司 用于青光眼的方法和药剂
US20230285350A1 (en) * 2020-07-15 2023-09-14 Lyotip, Inc. Formulations for tetracaine and lidocaine
CN116490211A (zh) * 2020-10-29 2023-07-25 株式会社泰俊制药 眼用组合物
CN116648485B (zh) * 2020-12-03 2025-08-29 贝克曼库尔特有限公司 用于稳定的台盼蓝溶液的组合物和方法
US20240058320A1 (en) * 2020-12-17 2024-02-22 Harrow Ip, Llc Mydriatic compositions and methods for fabricating thereof
CN116744904A (zh) * 2020-12-24 2023-09-12 参天制药株式会社 含有依匹斯汀或其盐和硫系抗氧化剂的经皮施予用医药组合物
US20240409405A1 (en) * 2021-01-25 2024-12-12 Lennham Pharmaceuticals, Inc. Products comprising deuterium-enriched water
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations
WO2022169959A1 (en) * 2021-02-04 2022-08-11 Sydnexis, Inc. Ophthalmic compositions for presbyopia
CA3208002A1 (en) * 2021-03-22 2022-09-29 Pierfrancesco Morosini Solid composition of indocyanine green and sodium fluorescein
US12392781B2 (en) 2021-05-04 2025-08-19 University Of Notre Dame Du Lac Deuterated indole heptamethine cyanine dyes
US11883382B2 (en) 2021-07-23 2024-01-30 Somerset Therapeutics, Llc Buffer-free ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US12029729B2 (en) 2021-07-23 2024-07-09 Somerset Therapeutics, Llc Chelated, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same
JP2025529178A (ja) * 2022-09-01 2025-09-04 オプティファイ・セラピューティクス・アクティエンゲゼルシャフト 眼科用組成物
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
JPWO2025004579A1 (https=) * 2023-06-30 2025-01-02

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (https=) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (https=) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
CA2250780A1 (en) 1996-04-10 1997-10-16 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (https=) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
AU779783B2 (en) 1999-05-17 2005-02-10 Eisai Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
ES2396598T3 (es) 2000-08-25 2013-02-22 Senju Pharmaceutical Co., Ltd. Preparaciones en forma de suspensiones acuosas
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL158904A0 (en) 2001-05-25 2004-05-12 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
JP2003063576A (ja) 2001-06-15 2003-03-05 Taisei Kako Co Ltd 分与容器
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
AU2004264974A1 (en) 2003-08-15 2005-02-24 Arius Two, Inc. Adhesive bioerodible transmucosal drug delivery system
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ579516A (en) 2004-01-27 2011-01-28 Osteotech Inc Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
MX2007009417A (es) 2005-02-04 2007-08-17 Univ Auburn Sistema de suministro de farmaco de contacto.
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
US20100022495A1 (en) 2005-11-01 2010-01-28 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) * 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
NZ584275A (en) 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
EP2508189A3 (de) 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Verwendung von Deuteriumoxid als Elastase-Inhibitor
EP2370054B1 (en) 2008-12-11 2015-10-07 Massachusetts Institute of Technology Contact lens drug delivery device
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
US8883214B2 (en) 2009-01-13 2014-11-11 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
EP2464387A4 (en) 2009-08-12 2013-05-15 Seros Medical Llc DEUTERATED WATER SOLUTION AND RIBOFLAVIN FOR EXTENDED OXYGEN SINGULET LIFETIME IN THE TREATMENT OF OCULAR TISSUE AND METHOD OF USE
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
EP2563303A4 (en) 2010-04-30 2013-11-06 Seros Medical Llc METHOD AND APPARATUS FOR TREATING OCULAR TISSUE USING COMBINED MODALITIES
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
EP2593056B1 (en) 2010-07-15 2020-10-21 Eyenovia, Inc. Drop generating device
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
US8530449B2 (en) 2010-09-09 2013-09-10 Assad S. Sawaya Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
BR112013021048A2 (pt) 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
CN103501764A (zh) 2011-03-03 2014-01-08 阿勒根公司 基于硅酮的眼科制剂
MX346312B (es) 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
KR101967938B1 (ko) * 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
WO2013079580A1 (en) 2011-11-29 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
JP6329130B2 (ja) 2012-04-10 2018-05-30 アイノビア，インコーポレイティド 噴霧エジェクタ機構、電荷分離及び制御可能な液滴電荷を提供する装置、並びに低投与量の点眼
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX2014013714A (es) 2012-05-11 2015-08-10 Cipla Ltd Composicion farmaceutica.
WO2013173321A1 (en) 2012-05-14 2013-11-21 Corinthian Ophthalmic, Inc. Laminar flow droplet generator device and methods of use
EA201492094A1 (ru) 2012-05-15 2015-04-30 Айновиа, Инк. Эжекторные устройства, способы, возбудители и схемы для них
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
WO2014161002A2 (en) 2013-03-29 2014-10-02 Onefocus Technology, Llc Drug delivery from contact lenses with a fluidic module
CA2911298C (en) 2013-05-06 2019-09-17 Kaohsiung Chang Gung Memorial Hospital A pharmaceutical composition comprising atropine and nsaid for treating myopia
SMT201900223T1 (it) * 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
JP6660939B2 (ja) 2014-08-13 2020-03-11 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 点眼剤からの保存剤除去
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
ES2929368T3 (es) 2016-05-25 2022-11-28 Singapore Health Serv Pte Ltd Composición acuosa que contiene atropina
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
MX387723B (es) 2016-09-19 2025-03-18 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
JP2020509085A (ja) 2017-02-21 2020-03-26 シンガポール ヘルス サービシーズ プライベート リミテッド アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法
RU2745603C1 (ru) 2017-05-11 2021-03-29 Невакар Инк. Фармацевтические композиции атропина
WO2019018749A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. COMPOSITION AND METHODS FOR THE TREATMENT OF MYOPIA
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
JP2023505841A (ja) 2019-12-16 2023-02-13 シドネキシス，インク． Ｄ２ｏを含む眼科用組成物
WO2022169959A1 (en) 2021-02-04 2022-08-11 Sydnexis, Inc. Ophthalmic compositions for presbyopia

Also Published As

Publication number Publication date
JP2018521000A (ja) 2018-08-02
US20200197410A1 (en) 2020-06-25
US12070466B2 (en) 2024-08-27
US20180147214A1 (en) 2018-05-31
EP3302426A4 (en) 2018-12-05
WO2016196367A1 (en) 2016-12-08
US11052095B2 (en) 2021-07-06
HK1248570A1 (zh) 2018-10-19
US20210283142A1 (en) 2021-09-16
US12168017B2 (en) 2024-12-17
EP3302426A1 (en) 2018-04-11
US20210393649A1 (en) 2021-12-23
CN107847432A (zh) 2018-03-27
US11052094B2 (en) 2021-07-06
US20250275983A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
US20250275983A1 (en) D2o stabilized pharmaceutical formulations
US20250186251A1 (en) Ophthalmic composition and delivery device thereof
US20240165098A1 (en) Ophthalmic composition
US20240139166A1 (en) Ophthalmic compositions for presbyopia
US20230041788A1 (en) Ophthalmic compositions comprising d2o
JP2026067867A (ja) Ｄ２ｏを含む眼科用組成物
HK40082459A (en) Ophthalmic compositions comprising d2o
HK40083012A (en) Ophthalmic composition
HK1231756B (zh) 眼用组合物
HK1231756A1 (en) Ophthalmic composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination